Novella Clinical Names Dr. Chris Smyth Managing Director of European and Asian Operations

STEVENAGE, England--(BUSINESS WIRE)--Novella Clinical, a Quintiles company, today announced the appointment of Chris Smyth, Ph.D., MBA as managing director of European and Asian operations.

Smyth joins Novella Clinical (Novella) with more than 20 years research and development experience in the pharmaceutical industry. Prior to joining Novella, he served as senior vice president of clinical development in the oncology division of INC Research. Smyth has led clinical research organizations (CROs) and biopharmaceutical companies in both Europe and the U.S., dealing exclusively in hematology and oncology drug development since 2003. He earned his Ph.D. in Reproductive Biology from the University of Edinburgh and an MBA from Henley Management College.

"We are fortunate to have someone as experienced as Dr. Smyth guiding our team and business objectives in Europe and Asia," said Novella Clinical Chief Operating Officer Rob King. "His depth of international leadership and oncology operations expertise will prove to be an invaluable resource as we continue to expand our services into new markets."

Based in Novella's European headquarters in Stevenage, England, Smyth will provide strategic leadership, organization and training resources for Novella's regional teams. Smyth also will lead oncology delivery operations in all markets outside the U.S. He succeeds Elizabeth Edwards, who will now serve as executive vice president of global operations, overseeing Novella's clinical monitoring division.

Novella established its European presence in Stevenage in 2009 and has more than 200 clinical research professionals in Europe.

About Novella Clinical

Novella Clinical, a Quintiles company, is a full service clinical research organization (CRO) with dual headquarters in Research Triangle Park, N.C. and Stevenage, England. Novella specializes in serving the unique needs of small and mid-size oncology companies, and medical device companies of all sizes. Founded in 1998, Novella integrates deep clinical and therapeutic expertise, operational excellence, and a superior level of customer service to streamline product development. For more information, visit www.novellaclinical.com.

Contacts

Novella Clinical
Kena Hudson, 00-1-562-508-5224
[email protected]

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.